Recent Updates
Recently added Catalysts
IMVT Positive Sentiment

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Monday, January 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunovant has announced it will report its financial results for Q3 2025 on February 6, 2026. The company will also provide a business update during the conference call. Investors can access the call via registration, and details will be available on the Immunovant website. The company focuses on developing therapies for autoimmune diseases.
Price reaction · baseline $26.01 (2026-01-23 close) · hit pre-market · clean, no other IMVT news in the window
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is actively engaging with investors by reporting financial results.
  • The company is dedicated to developing innovative therapies for autoimmune diseases.
  • The upcoming business update indicates ongoing progress and transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
7.3%
average across 5 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
IMVT-1402
Phase 3 · Generalized Myasthenia Gravis

Full Press Release Details

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using thisregistration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website athttps://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About ImmunovantImmunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visitimmunovant.com.

Contacts:InvestorsKeyur Parekhkeyur.parekh@roivant.com

Frequently Asked Questions

When will Immunovant report its Q3 2025 results?

Immunovant will report its Q3 2025 financial results on February 6, 2026.

How can I access the Immunovant conference call?

You can access the conference call by registering online using the provided link.

What is the focus of Immunovant's business?

Immunovant is focused on developing therapies for autoimmune diseases.

Where can I find the archived webcast of the call?

The archived webcast will be available on Immunovant's website after the call.

ShareAdd on Google
Tags: IMVT Viatris Investor Conferences Healthcare Immunovant financial results business update autoimmune diseases
Last updated: Jan 26, 2026

Biotech snapshot

Cash runway
$798M liquidity · $41M/mo burn
~19 mo
Low dilution risk
Lead asset
IMVT-1402Phase 3
Generalized Myasthenia Gravis →

Catalyst track record

+85%
best trade around IMVT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IMVT.

See every catalyst's timing & PoA →